CoChat

Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo

Zhu, Qing, Yang, Jun, Han, Suxia, Liu, Jihong, Holzbeierlein, Jeffery, Thrasher, J. Brantley, Li, Benyi · 2011 · The Prostate
Cited by 98

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Glycogen synthase kinase 3 (GSK‐3) has been regarded as a potential therapeutic target for multiple human cancers. We previously reported that suppression of GSK‐3 activity with lithium chloride (LiCl) or small chemical inhibitors impaired cellular DNA synthesis and reduced cell proliferation in prostate cancer cells. Therefore, in this study, we extended this in vitro findings to in vivo settings in order to establish a proof of concept that inhibition of GSK‐3 activity is feasible in suppressing tumor growth of prostate cancer in vivo. METHODS: In this study, we used three GSK‐3 inhibitors, LiCl, TDZD‐8, and L803‐mts, which are structurally unrelated and non‐ATP competitive. Human prostate cancer cell lines PC‐3 and C4‐2 were used for nude mouse xenograft models. The autochthonous transgenic prostate cancer TRAMP mice were used for testing GSK‐3 inhibitor's effect on tumor development. Anti‐Ki‐67 and BrdU immunohistochemistry was used to determine cell proliferation. The pE2F‐TA‐LUC (E2F‐LUC) luciferase reporter assay and gene specific small interferencing RNA technique were used to examine C/EBP involvement in GSK‐3 inhibitor‐induced E2F‐1 suppression. RESULTS: Using mouse xenograft models, we demonstrated that LiCl and TDZD‐8 significantly suppressed tumor development and growth of subcutaneous xenografts derived from human prostate cancer cells. Similarly, in the TRAMP mice, TDZD‐8 and L803‐mts reduced the incidence and tumor burden in the prostate lobes. Consistent with our previous in vitro findings, GSK‐3 inhibitors significantly reduced BrdU incorporation and Ki67‐positive cells in xenograft tumors and mouse cancerous prostates compared to the control. Further analysis revealed that following GSK‐3 inhibition, C/EBPα, a negative cell cycle regulator, was remarkably accumulated in xenograft tumors or in cultured prostate cancer cells. Meanwhile, knocking down C/EBPα expression abolished GSK‐3 inhibition‐induced suppression of E2F1 transactivation, suggesting that C/EBPα accumulation is involved in GSK‐3 inhibition‐induced anti‐tumor effect. CONCLUSION: Taken together, these results suggest that GSK‐3 inhibition has the potential as a therapeutic strategy for prostate cancer intervention, although further pre‐clinical and clinical testing are desirable. Prostate 71:835–845, 2011. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.21300

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 98

Metadata

Authors
Zhu, Q., Yang, J., Han, S., Liu, J., Holzbeierlein, J., Thrasher, J. B., & Li, B.
Venue
The Prostate
Publisher
Wiley
Published
2010-10-28
Volume
71
Issue
8
Pages
835-845
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W1994994301
Cited by
98
References
2
FWCI
1.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. https://app.cochat.ai/papers/10.1002/pros.21300
The paper
Zhu, Q., Yang, J., Han, S., Liu, J., Holzbeierlein, J., Thrasher, J. B., & Li, B. (2011). Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. The Prostate. https://doi.org/10.1002/pros.21300

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.